Table 3.

Areas of future research in the mutant prevention concentration in M. tuberculosis

In vitro	WGS and quantitative drug susceptibility testing to correlate mutations with phenotypic resistance
	determine MPC for current and experimental therapies
	stratify MPC by resistance mutation and strain
In vivo	validation of the MSW for all TB drugs
	pharmacokinetics and pharmacodynamics at MPC
	safety and tolerability at MPC
Clinical	pharmacokinetics of current dosing of second-line therapies in children, and relationship to clinical outcome
	development of targets based on Cmax/MPC and AUC/MPC
	correlate adverse effects with serum drug concentrations in children

MSW, mutation selection window.